TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.810nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.890nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.980nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.990nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.80nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.10nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.10nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.20nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.30nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 7.60nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 9.40nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Antagonist activity at PAR4 in human platelet rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 38nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 67nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 74nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 110nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 220nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 240nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 240nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 270nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 350nMAssay Description:Antagonist activity at PAR4 in human washed platelets assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mins f...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 390nMAssay Description:Antagonist activity at PAR4 in human platelet rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:Antagonist activity at PAR4 in human platelet rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 440nMAssay Description:Antagonist activity at PAR4 in human platelet rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Bristol-Myers Squibb Research & Development
Curated by ChEMBL
Affinity DataIC50: 480nMAssay Description:Antagonist activity at PAR4 in human platelet rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair